Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lonza Group Ltd (LONN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
755.00+4.00 (+0.53%)
At close: 5:31PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close751.00
Open754.40
Bid0.00 x 0
Ask0.00 x 0
Day's Range749.40 - 758.00
52 Week Range516.20 - 785.40
Volume88,546
Avg. Volume136,138
Market Cap56.084B
Beta (5Y Monthly)0.42
PE Ratio (TTM)79.28
EPS (TTM)9.52
Earnings DateJul 23, 2021
Forward Dividend & Yield3.00 (0.40%)
Ex-Dividend DateMay 10, 2021
1y Target Est762.54
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LONN.SW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 3-Moderna says COVID-19 vaccine supply outside United States to slow down

      Moderna said on Tuesday its COVID-19 vaccine manufacturing partners outside the United States are facing delays due to laboratory testing operations that have occurred in the past few days, slowing the supply of the shot to these markets. The vaccine maker's comments come after South Korean health officials said earlier in the day that Moderna has delayed its late-July vaccine shipment schedule for the country to August due to supply problems. "We are currently not reserving safety stock to allow vaccines to be delivered faster, which means that we do not have stock in storage to smooth these types of shortfalls or delays," a Moderna spokesperson said.

    • Reuters

      Vaccine business helps Lonza lift 2021 sales outlook

      ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.

    Advertisement
    Advertisement